It is an enzyme-linked immunosorbent assay (ELISA) that can find detectable or not detectable levels of anti-JCV antibodies in the plasma. Biogen is looking for genetic variation in the host and virus that could be linked to higher susceptibility to develop PML. I don't expect much from this study.